Health & Fitness
Health and Fitness
Health and Fitness
Mon, April 13, 2009Fri, April 10, 2009Thu, April 9, 2009Wed, April 8, 2009Tue, April 7, 2009Mon, April 6, 2009Fri, April 3, 2009Thu, April 2, 2009Wed, April 1, 2009Tue, March 31, 2009Mon, March 30, 2009Fri, March 27, 2009Thu, March 26, 2009Wed, March 25, 2009Tue, March 24, 2009Mon, March 23, 2009Fri, March 20, 2009Thu, March 19, 2009Wed, March 18, 2009Tue, March 17, 2009Mon, March 16, 2009Sun, March 15, 2009Fri, March 13, 2009Thu, March 12, 2009Wed, March 11, 2009Tue, March 10, 2009Mon, March 9, 2009Fri, March 6, 2009Thu, March 5, 2009Wed, March 4, 2009Tue, March 3, 2009Mon, March 2, 2009Fri, February 27, 2009Thu, February 26, 2009Wed, February 25, 2009Tue, February 24, 2009Mon, February 23, 2009Sun, February 22, 2009Fri, February 20, 2009NeuroInvestment: Migraine Therapeutics Reviewed by NeuroInvestment
Published in Health and Fitness on Monday, March 2nd 2009 at 11:02 GMT, Last Modified on 2009-03-02 11:03:21 by Market Wire
CARDIFF, CA--(Marketwire - March 2, 2009) - NI Research has released the March issue of NeuroInvestment, which reviews the status and prospects of migraine therapeutics. Triptans are successful, but far from perfect in terms of rapidity and duration of effect, and the cardiovascular side effect profile. The next generation of migraine therapeutics involves two main categories: alternative delivery methods, primarily for rapid migraine relief, and novel mechanisms of action.
Among the companies developing alternative delivery methods are Alexza Pharmaceuticals (
The March issue of NeuroInvestment also assesses Lundbeck's acquisition of Ovation Pharmaceuticals; the safety questions that remain unresolved regarding neural stem cell implantation; and evaluates Accera, which has just launched Axona as a 'medical food' for Alzheimer's.
About NeuroInvestment: NeuroInvestment is the independent, monthly review of the neurotherapeutics area. A one-year subscription is $1700, email or hardcopy. Add $250 for dual delivery, add $50 for airmail delivery outside North America. A three-month trial subscription is $500.
A $1200 introductory rate for new subscribers only is currently being offered for subscription orders placed before April 1.
A recent sample issue of NeuroInvestment is available for download at: [ http://www.neuroinvestment.com/NewNeuroInvestment.html ].
NI Research is the leading publisher of independent research on the neuropharmaceutical/therapeutic industry. NI Research has published NeuroInvestment since 1995, the Private CNS Company Review since 2003; and CNS Disorders/Therapeutics, an annual compendium of all neuro-oriented R&D programs, since 2007.
NI Research has developed an unmatched information base regarding both publicly and privately held neuro-oriented companies, and offers M&A/licensing consultation and custom research for large and small pharmaceutical firms.
